Surfing the MASH Tsunami

Send us Fan Mail Study co-authors Stephen Harrison, Naim Alkhouri and Samer Gawrieh suggest that current estimates of NAFLD and NASH populations in the US may be meaningfully understated. Earlier this year, Drs. Harrison, Alkhouri, Gawrieh and seven co-authored published a paper in the Journal of Hepatology titled, "Prospective evaluation of the prevalence of non-alcoholic fatty liver disease...

Send us Fan Mail After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to conisder key takeaways from the Congress. This conversation is organized around competing strategies for diagnostic testing as the NASH market evolves. After hearing presentations from 43 speakers at the Fourth Global NASH Congress, six SurfingNASH...

Send us Fan Mail After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This conversation is organized around adoption of non-invasive testing in clinical development and when drugs will come to market. After hearing presentations from 43 speakers at the Fourth Global NASH Cong...

Send us Fan Mail After having time to think, six of the panelists who covered sessions at the Fourth Global NASH Congress get together one more time to consider key takeaways from the Congress. This conversation is organized around changes in treatment paradigms and guidelines. After hearing presentations from 43 speakers at the Fourth Global NASH Congress, six SurfingNASH panelists convene once m...

Send us Fan Mail The SurfingNASH coverage team from the Fourth Global NASH Congress convenes one more time to consider key takeaways from the Congress. Manal Abdelbalek, Naim Alkhouri, Ian Rowe, Suneil Hosmane, Louise Campbell and Roger Green all share high points, opportunities and lingering questions. On April 28 and 29, 2021, over 175 Fatty Liver stakeholders from across the globe convened virt...

Send us Fan Mail The SurfingNASH Team has curated over three hours of recordings from the Fourth Global NASH Congress to highlight pieces that discuss the current and future states of diagnostics in Fatty Liver disease. You will hear Manal Abdelmalek, Naim Alkhouri, Suneil Hosmane, Ian Rowe, Jörn Schattenberg, Louise Campbell and Roger Green sharing opinions and debating issues. Discussions about...

Send us Fan Mail Ian Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise and Roger as they keep discussing Day Two of the 4th Global NASH Congress. On April 29, over 175 NASH stakeholders from across the globe met virtually to hear 20 presentations from leaders in academia and industry. SurfingNASH selected 9 presentations to discuss in a session recorded right after the conferenc...

Send us Fan Mail Naim Alkhouri, Ian Rowe and GenFit Global Diagnostics Leader Suneil Hosmane join Louise Campbell and Roger Green to review presentations from Day Two at the 4th Global NASH Congress. On April 29, over 175 NASH stakeholders from across the globe met virtually to hear 20 presentations from leaders in academia and industry. SurfingNASH selected 9 presentations to discuss in a session...

Send us Fan Mail Manal Abdelmalek, Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review presentations from Day One at the 4th Global NASH Congress. On April 28, over 175 NASH stakeholders from across the globe will meet virtually to hear 23 presentations from leaders in academia and industry. SurfingNASH has selected 11 presentations to discuss in a sess...

Send us Fan Mail The Surfers explore the impact that NASHmap, the first Machine Learning model that can identify patients likely to have NASH, can have on clinical trials and patient treatment. Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Optum de-identified EHR dataset. The model includes 14 variables, some obvious, others less so, tha...

Send us Fan Mail The Surfers analyze outputs from NASHmap, the first Machine Learning model that can identify patients likely to have NASH, to learn what we can about the disease and how to think about its value for racial and ethnic minorities. Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Optum de-identified EHR dataset. The model incl...

Send us Fan Mail Jörn Schattenberg discusses NASHmap, the first Machine Learning model that can identify patients likely to have NASH in clinical settings. Louise, Roger and guest Dr. Kris Kowdley join Jörn to discuss the model from academic, patient treatment and statistical perspectives. Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Op...

Send us Fan Mail Jörn Schattenberg discusses the issues that drove the project to develop a Machine Learning model that can identify patients likely to have NASH in clinical settings, and discusses key elements of study and model design. Prof. Schattenberg and colleagues built the NASHmap model from a NIDDK database and validated it using the Optum de-identified EHR dataset. The model includes 14...

Send us Fan Mail Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review pharmacotherapy themes to be covered at the 4th Global NASH Congress. Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review drug-related topics covere...

Send us Fan Mail Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review holistic and patient-centric issues to be covered at the 4th Global NASH Congress. Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review patient-centr...

Send us Fan Mail Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to review non-invasive testing themes to be covered at the 4th Global NASH Congress. Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for the 4th Global NASH Congress. In this conversation, Jörn Schattenberg joins them to review non-invasive testing...

Send us Fan Mail Jörn Schattenberg and GenFit Global Diagnostics Leader Suneil Hosmane join the Surfers to survey the agenda for the 4th Global NASH Congress. The 4th Global NASH Congress has presentations of interest on a broad array of topics. Congress Keynote Speaker Suneil Hosmane joins Louise Campbell and Roger Green to form the coverage team for this event. Along with Jörn Schattenberg, they...

Send us Fan Mail Roger Green conducts one-on-one interviews with Stephen Harrison and Alina Allen to explore specific issues regarding new issues and insights for clinical research and drug development resulting from the work of Dr. Allen and her colleagues. Stephen Harrison discusses the important contribution this paper makes to our knowledge about disease progression. He then suggests several t...

Send us Fan Mail The group focuses on the patient treatment implications of being able to identify the patients who are at risk of rapid progression, particularly among those with compensated cirrhosis. Louise Campbell and Alina Allen discuss the psychological and practical aspects of treating patients (particularly those with cirrhosis) who know they are risk of imminent disease progression, whil...

Send us Fan Mail Alina Allen shares the results of her recent Clinical Gastroenterology and Hepatology paper on predictive value of MR Elastography in determining likelihood of progress for NASH patients exhibiting F1 - F3 disease and separately, those living with cirrhosis. Using a longitudinal data base of over 800 patients spanning 12 years, Dr. Allen and her colleagues published analysis demon...

Send us Fan Mail Alina Allen of the Mayo Clinic joins the Surfers to discuss her recent publication demonstrating that kPa scores from MR Elastography can predict the course of disease for non-cirrhotic and cirrhotic patients and consider its implications for clinical trials and every day patient treatment. This episode has an unusual format. First, Alina Allen discusses her study and its implicat...

Send us Fan Mail Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. This conversations starts by questioning the incremental value of ultrasound in the diagnostic process and proceeds to consider the goals of screening and two specific challenges. This conversation focuses on how to improve diagnostic accuracy and speed, sta...

Send us Fan Mail Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversations to consider the goals for a therapy that, in Ian's words, "treats the patient and not the NASH." Ian Rowe and colleagues have created a model to assess the tradeoff of liver risk reduction vs. CVD risk reduction at...

Send us Fan Mail Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversation to consider what "efficiency" means in the context of patient diagnosis and whether "less expensive" is always more efficient. In this conversation, he questions whether positioning a second blood-based test be...

Send us Fan Mail Ian Rowe joins the Surfers to discuss more detailed findings from the on-going analyses he and Richard Parker are conducting on abnormal liver tests among patients in Leeds, UK. In this episode, Ian discusses three specific findings that seem paradoxical but make complete sense. As Stephen points out several time over the course of the episode, this work demonstrates how complicat...